In Situ Thrombosis of Small Pulmonary Arteries in Pulmonary Hypertension Developing after Chemotherapy for Malignancy

Table 1

Details of patients with pulmonary hypertension after chemotherapy.

Case	Age, sex	Neoplasm	Treatment for neoplasm	Period from chemotherapy to PH onset	Clinical diagnosis cause of death	Pathological findings	Lung specimen
1	46, M	Malignant lymphoma	Surgical resection +; chemotherapy	8 years	IP	In situ thrombosis of SPA and veins	Biopsy
2	6, F	NB	Surgical resection +; AutoPBSCT () + high-dose chemotherapy	7 days	IP, PVOD	In situ thrombosis of SPA and veins	Biopsy
3	2, F	ALL	Umbilical cord blood transplant () + high-dose chemotherapy	10 days	PAH,; Congenital protein C deficiency	In situ thrombosis of SPA	Biopsy
4	2, M	RMS	Chemotherapy +; Proton therapy	During chemotherapy	Hepatic venoocclusive disease unknown	In situ thrombosis of SPA and veins	Autopsy
5	5, M	Burkitt’s; Lymphoma	Chemotherapy	During chemotherapy	PVOD refractory right HF]	PVOD	Autopsy
6	3, M	MB	Surgical resection +; chemotherapy	9 months	s/o PAH, PVOD; IP	IPAH, IP	Autopsy
7	2, F	AML	Allogeneic bone marrow transplant + high-dose chemotherapy	2 months	s/o PVOD, cGVHD IP	Plexogenic arteriopathy, IP	Autopsy

ALL = acute lymphocytic leukemia; AML = acute myelogenous leukemia; AutoPBSCT = autologous peripheral blood stem cell transplantation; cGVHD = chronic graft versus host disease; F = female; HF = heart failure; IP = interstitial pneumonia; IPAH = idiopathic pulmonary arterial hypertension; M = male; MB = medulloblastoma; NB = neuroblastoma; PAH = pulmonary arterial hypertension; PH = pulmonary hypertension; PVOD = pulmonary venoocclusive disease; RMS = rhabdomyosarcoma; SPA = small pulmonary arteries.